Skip to main
OPK
OPK logo

OPKO Health (OPK) Stock Forecast & Price Target

OPKO Health (OPK) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 36%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

OPKO Health Inc. is strategically positioning itself by focusing on its drug development capabilities, resulting in a stronger balance sheet and a potentially profitable remaining lab business following recent divestitures. The company demonstrated financial resilience with a total revenue of $183.6 million in 4Q24, indicating a 0.9% year-over-year growth, surpassing projections and showcasing improved operational efficiencies. Additionally, net income was reported at $14.0 million, attributed largely to a significant realized gain from the sale of shares, suggesting a favorable trajectory for future profitability and operational performance.

Bears say

OPKO Health Inc. has reported a significant decline in revenue across its operations, with Diagnostics services revenue dropping 17% year-over-year to $103.1 million, primarily attributed to reduced clinical test volumes following asset sales. The total revenue for full-year 2024 has also decreased by 17% year-over-year to $713.1 million, compounded by a 13% decline in pharmaceutical products revenue due to unfavorable foreign currency exchange fluctuations. Additionally, persistent risks such as lower-than-projected growth in diagnostics services, challenges in regulatory approvals for new pharmaceuticals, and competition could hinder future financial performance.

OPKO Health (OPK) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 36% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OPKO Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OPKO Health (OPK) Forecast

Analysts have given OPKO Health (OPK) a Buy based on their latest research and market trends.

According to 11 analysts, OPKO Health (OPK) has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OPKO Health (OPK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.